Pulmatrix ROE

Mitä Pulmatrix tekee? Pulmatrix Inc is a clinical stage biotechnology company based in Lexington, Massachusetts, focused on developing inhaled therapeutic products for respiratory and other diseases. The company went public via an IPO on March 21, 2014, and currently employs two full-time staff members. Pulmatrix utilizes its proprietary dry powder delivery technology, iSPERSE, to create inhaled therapies designed for local or systemic drug delivery to the lungs. The iSPERSE platform enables the formulation of small or large molecule drugs into dry powder form, engineered to be small, dense particles with optimal dispersibility and airway delivery. This technology is compatible with various dry powder inhaler devices and supports a wide range of drug substances, including small molecules and biologics. Pulmatrix has several therapeutic candidates in development, including Pulmazole, PUR1800, PUR5700, PUR3000, and PUR4000. The company's website is www.pulmatrix.com. Pulmatrix operates within the pharmaceuticals sector of the health care industry, targeting serious respiratory conditions through innovative inhaled drug delivery solutions. Pulmatrix on yksi Eurpooliin suosituimmista yhtiöistä.